Tango Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 155

Employees

  • Stock Symbol
  • TNGX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $21.75
  • (As of Friday Closing)

Tango Therapeutics General Information

Description

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Contact Information

Website
www.tangotx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 201 Brookline Avenue
  • Suite 901
  • Boston, MA 02215
  • United States
+1 (857)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 201 Brookline Avenue
  • Suite 901
  • Boston, MA 02215
  • United States
+1 (857)

Tango Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tango Therapeutics Stock Performance

As of 20-Nov-2026, Tango Therapeutics’s stock price is $21.75. Its current market cap is $3.68B with 169M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$21.75 $22.71 $8.30 - $34.39 $3.68B 169M 3.4M -$1.37

Tango Therapeutics Financials Summary

As of 30-Sep-2026, Tango Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 3,224,831 1,075,191 76,269 689,324
Revenue 0 62,384 42,069 36,527
EBITDA (220,982) (104,920) (135,484) (105,829)
Net Income (207,998) (101,594) (130,302) (101,744)
Total Assets 1,033,460 398,690 316,492 402,567
Total Debt 31,179 33,570 36,493 38,920
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Tango Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Tango Therapeutics‘s full profile, request access.

Request a free trial

Tango Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Tango Therapeutics‘s full profile, request access.

Request a free trial

Tango Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the
Drug Discovery
Boston, MA
155 As of 2026

Wilmington, DE
 

Saint-Laurent, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tango Therapeutics Competitors (40)

One of Tango Therapeutics’s 40 competitors is Prelude Therapeutics, a Formerly VC-backed company based in Wilmington, DE.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Prelude Therapeutics Formerly VC-backed Wilmington, DE
Repare Therapeutics Formerly VC-backed Saint-Laurent, Canada
Ayala Pharmaceuticals Corporation Wilmington, DE
Arcus Biosciences Formerly VC-backed Hayward, CA
Innovimmune Biotherapeutics Accelerator/Incubator Backed New York, NY
You’re viewing 5 of 40 competitors. Get the full list »

Tango Therapeutics Patents

Tango Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026148158-A1 Compounds and methods of use Pending 31-Dec-2024
WO-2026148070-A1 Compounds and methods of use Pending 30-Dec-2024
WO-2026148072-A1 Compounds and methods of use Pending 30-Dec-2024
WO-2026148073-A1 Compounds and methods of use Pending 30-Dec-2024
WO-2026128522-A1 Prmt5 inhibitor for the treatment of cancer Pending 09-Dec-2024 A61K31/4162
To view Tango Therapeutics’s complete patent history, request access »

Tango Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tango Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Tango Therapeutics‘s full profile, request access.

Request a free trial

Tango Therapeutics Acquisitions (1)

Tango Therapeutics’s most recent deal was a Merger/Acquisition with BCTG Acquisition. The deal was made on 10-Aug-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
BCTG Acquisition 10-Aug-2021 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Tango Therapeutics’s complete acquisitions history, request access »

Tango Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.07 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Tango Therapeutics’s complete esg history, request access »

Tango Therapeutics FAQs

  • When was Tango Therapeutics founded?

    Tango Therapeutics was founded in 2017.

  • Where is Tango Therapeutics headquartered?

    Tango Therapeutics is headquartered in Boston, MA.

  • What is the size of Tango Therapeutics?

    Tango Therapeutics has 155 total employees.

  • What industry is Tango Therapeutics in?

    Tango Therapeutics’s primary industry is Drug Discovery.

  • Is Tango Therapeutics a private or public company?

    Tango Therapeutics is a Public company.

  • What is Tango Therapeutics’s stock symbol?

    The ticker symbol for Tango Therapeutics is TNGX.

  • What is the current stock price of Tango Therapeutics?

    As of 20-Nov-2026 the stock price of Tango Therapeutics is $21.75.

  • What is the current market cap of Tango Therapeutics?

    The current market capitalization of Tango Therapeutics is $3.68B.

  • Who are Tango Therapeutics’s competitors?

    Prelude Therapeutics, Repare Therapeutics, Ayala Pharmaceuticals, Arcus Biosciences, and Innovimmune Biotherapeutics are some of the 40 competitors of Tango Therapeutics.

  • What is Tango Therapeutics’s annual earnings per share (EPS)?

    Tango Therapeutics’s EPS for 12 months was -$1.37.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process